<DOC>
	<DOCNO>NCT01705574</DOCNO>
	<brief_summary>This study evaluate safety , efficacy , tolerability regimen contain elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate ( Stribild® ; E/C/F/TDF ) fixed-dose combination ( FDC ) versus ritonavir ( RTV ) -boosted atazanavir ( ATV ) plus emtricitabine/tenofovir disoproxil fumarate ( Truvada® ; FTC/TDF ) HIV-1 infect , antiretroviral treatment-naive adult woman . This study consist two phase : Double-Blinded Treatment Phase ( 48 week ) Open-Label Extension ( OLE ) Phase ( 48 week ) . After 48 week blind treatment , participant continue take blind study drug 12 week return Unblinding Visit Week 60 . Participants virologically suppress Week 48 Double-Blinded Treatment Phase option enter OLE Phase .</brief_summary>
	<brief_title>Safety Efficacy E/C/F/TDF ( Stribild® ) Versus RTV-Boosted ATV Plus FTC/TDF ( Truvada® ) HIV-1 Infected , Antiretroviral Treatment-Naive Women</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Elvitegravir , Cobicistat , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>Female ( birth ) , age ≥ 18 year Ability understand sign write informed consent form Plasma HIV1 RNA level ≥ 500 copies/mL No prior use approved investigational antiretroviral drug length time Screening genotype report must show sensitivity emtricitabine ( FTC ) , tenofovir disoproxil fumarate ( TDF ) atazanavir ( ATV ) boost ritonavir ( RTV ) Normal ECG Adequate renal function : Estimated glomerular filtration rate ≥ 70 mL/min accord Cockcroft Gault formula Hepatic transaminases ≤ 5 x upper limit normal ( ULN ) Total bilirubin ≤ 1.5 mg/dL Adequate hematologic function Serum amylase ≤ 5 x ULN Women childbearing potential must agree utilize protocol recommend contraception method nonheterosexually active , practice sexual abstinence screen throughout duration study period 30 day follow last dose study drug Women utilize hormonal contraceptive one birth control method must use method least three month prior study dose . A new AIDS defining condition diagnose within 30 day Females receive drug treatment Hepatitis C , female anticipate receive treatment Hepatitis C course study Females experience decompensated cirrhosis Females breastfeed Positive serum pregnancy test ( female childbearing potential ) Have implant defibrillator pacemaker Have ECG pulse rate interval ≥ 220 msec Current alcohol substance use may potentially interfere female 's study compliance History malignancy within past 5 year ongoing malignancy cutaneous Kaposi 's sarcoma ( KS ) , basal cell carcinoma , resect , noninvasive cutaneous squamous carcinoma Active , serious infection require parenteral antibiotic antifungal therapy within 30 day prior baseline Participation clinical trial without prior approval Any clinical condition prior therapy would make female unsuitable study unable comply dose requirement Females receive ongoing therapy disallow medication , include drug use elvitegravir , cobicistat , FTC , TDF , ATV , RTV ; female know allergy excipients Stribild® tablet , Truvada® tablet , atazanavir capsule ritonavir tablet</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>HIV</keyword>
	<keyword>Treatment-Naive</keyword>
	<keyword>Women</keyword>
	<keyword>WAVES</keyword>
</DOC>